Oxurion NV represents values of excellence, innovation, and patient-centricity in the field of biopharmaceuticals. The company is committed to developing and commercializing life-changing therapies for the treatment of retinal diseases, including diabetic eye disease. Oxurion NV's corporate philosophy revolves around collaborative partnerships, scientific expertise, and a strong focus on clinical research, aiming to improve the lives of patients worldwide. With a dedicated team of experts and a robust pipeline of potential therapies, Oxurion NV stands at the forefront of driving advancements in ocular health and delivering sustainable value to its stakeholders.

Oxurion NV, a renowned biopharmaceutical company, is primarily present in various countries and regions across the globe. This includes the United States, Europe, Asia, and other key markets. With its strong international presence, Oxurion NV has established a significant footprint in the pharmaceutical industry. Their presence in these diverse regions allows the company to reach a broad range of patients and stakeholders, ensuring the potential for growth and collaboration.

Some significant milestones that Oxurion NV has achieved include the successful completion of Phase 2 clinical trials for its innovative treatment for diabetic macular edema (DME) called THR-149. The company has also received Fast Track designation from the U.S. Food and Drug Administration (FDA) for THR-149, which recognizes the potential of the therapy to address an unmet medical need. In addition, Oxurion NV has made progress in expanding its global reach by initiating clinical trials in Europe and the US for THR-687, a treatment for diabetic retinopathy. These milestones demonstrate Oxurion NV's commitment to advancing novel therapies for retinal diseases.

Oxurion NV, formerly known as ThromboGenics NV, is a biopharmaceutical company focused on the development of innovative treatments for eye diseases. Established in 1991, Oxurion NV has a rich history in the ophthalmic sector. The company specializes in researching and developing therapies targeting disorders related to the retina, particularly its leading product candidate, THR-317. Oxurion NV prides itself on its advanced drug discovery platforms and its commitment to addressing unmet medical needs in the field of ophthalmology. With a strong research background and dedication to advancing eye care, Oxurion NV has become a renowned player in the pharmaceutical industry.

The main competitors of Oxurion NV in the market include companies such as Novartis AG, Regeneron Pharmaceuticals Inc., and Roche Holding AG.

Oxurion NV primarily operates in the biotechnology and pharmaceutical industries.

The business model of Oxurion NV is focused on the development and commercialization of innovative treatments for diabetic eye diseases. The company specializes in the research of therapeutic approaches targeting the retina and the vascular structures of the eye. Their primary product candidate is THR-149, a potent plasma kallikrein inhibitor designed to address vision loss. By leveraging their expertise and cutting-edge technology, Oxurion NV aims to provide effective and safe solutions for patients suffering from diabetic macular edema and related conditions. Through strategic partnerships and in-house capabilities, the company strives to advance ophthalmic therapies and improve the quality of life for individuals affected by these diseases.

Det Oxurion P/E-forhold er -0,00.

Oxurion KUV er 0.

AlleAktien Kvalitetsscore for Oxurion er 2/10.

Omsætningen kan i øjeblikket ikke beregnes for Oxurion.

Den forventede Oxurion indtjening er -10,64 mia. EUR.

Oxurion NV is a publicly traded biopharmaceutical company focused on the development of therapeutic medicines for the treatment of eye diseases. The company is headquartered in Belgium and has offices in the USA and Ireland. The business model of Oxurion NV consists of three different divisions: research and development, the clinical trial process, and the marketing of its products. Oxurion's research and development department focuses on exploring novel therapy approaches for the treatment of retinal diseases such as diabetic macular edema (DME) and age-related macular degeneration (AMD). Oxurion utilizes innovative technologies such as anti-VEGF therapies and STB-SD technology to manufacture its products. Oxurion's clinical trial program includes Phase I to III clinical studies and aims to prove the efficacy and safety of its products. The company collaborates closely with leading clinicians and network partners to validate its research findings and ensure that its products meet high-quality standards. Oxurion's products include two main product lines: THR-149 and THR-687. THR-149 is a novel anti-VEGF therapy approach for the treatment of DME, currently being tested in Phase II clinical trials. THR-687 is a novel pan-RGD inhibitor targeting the treatment of DME and nAMD, currently being tested in Phase I clinical trials. Oxurion markets its products through a wide range of channels, including direct sales teams, marketing and distribution partnerships, and international licensing agreements. The company is focused on building long-term relationships with its customers and business partners and works closely with them to ensure that its products are effectively utilized in practice. In summary, the business model of Oxurion NV is based on creating innovative therapy approaches for the treatment of eye diseases. With its broad range of research, development, testing, and marketing activities, the company is well positioned to succeed in this rapidly growing market and achieve long-term positive results.

Oxurion udbetaler et udbytte på 0 EUR fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Oxurion, eller selskabet udbetaler ikke udbytte.

ISIN'en for Oxurion er BE0003846632.

WKN for Oxurion er A0J30B.

Tickeren for Oxurion er OXUR.BR.

I løbet af de sidste 12 måneder betalte Oxurion en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Oxurion sandsynligvis betale en dividende på 0 EUR.

Udbytteafkastet for Oxurion er i øjeblikket .

Oxurion betaler kvartalsvis udbytte. Dette uddeles i månederne .

Oxurion betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 EUR. Dette svarer til et dividendeafkast på 0 %.

Oxurion bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Oxurion fra den 9.7.2024 på 0 EUR, skulle du have haft aktien i din portefølje før ex-datoen den 9.7.2024.

Udbetalingen af det sidste udbytte blev foretaget den 9.7.2024.

I løbet af 2023 udbetalte Oxurion 0 EUR i form af dividender.

Udbytterne fra Oxurion udbetales i EUR.